Benzyl 1-Amino-3-Azabicyclo[3.1.0]hexane-3-Carboxylate: Lab Guide
Benzyl 1-Amino-3-Azabicyclo[3.1.0]hexane-3-Carboxylate: Lab Guide
benzyl 1-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate is a strained bicyclic amine building block featuring a free primary amino group and a benzyloxycarbonyl (Cbz)-protected nitrogen, making it a versatile intermediate for the synthesis of conformationally constrained peptidomimetics and biologically active small molecules.
- Product SKU
- B175650
- IUPAC Name
- benzyl 1-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate
- Core Scaffold
- 3-azabicyclo[3.1.0]hexane (pyrrolidine fused cyclopropane)
- Protecting Group
- Cbz (benzyloxycarbonyl) on ring nitrogen
- Key Functional Group
- Free primary amine at C-1 (quaternary carbon)
- Primary Application
- Medicinal chemistry scaffold, peptidomimetic synthesis
- Recommended Storage
- Cool, dry, well-ventilated area; away from moisture and light
Compound Overview and Structural Features
Benzyl 1-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate (Aladdin SKU: B175650) belongs to a class of saturated, strained bicyclic amines that have attracted significant interest in modern drug discovery. The core 3-azabicyclo[3.1.0]hexane framework consists of a five-membered pyrrolidine ring fused to a cyclopropane ring, imposing substantial conformational rigidity on any molecule that incorporates it.
The compound carries two distinct nitrogen-bearing features: a Cbz-protected secondary amine incorporated within the bicyclic ring at the N-3 position, and a free primary amine positioned at the quaternary C-1 carbon. The quaternary nature of C-1 means the amine is sterically defined, providing a handle for chemoselective derivatization without risk of epimerization at that centre.
The internal ring strain imparted by the fused cyclopropane influences both the electronic character and the three-dimensional shape of the molecule, properties that are increasingly exploited to improve the pharmacokinetic profiles of drug candidates by reducing planarity and increasing sp3 character (Fsp3).
Handling, Safety and Storage Guidelines
Personal Protective Equipment (PPE): When handling benzyl 1-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate, wear appropriate laboratory PPE including nitrile gloves, safety glasses or goggles, and a laboratory coat. Work in a well-ventilated fume hood to minimize inhalation exposure to fine particles or vapors.
Storage Conditions: Store the compound in a tightly sealed container in a cool, dry, and well-ventilated area, away from direct light and moisture. As with most primary amine-containing building blocks, exposure to air and moisture should be minimized to prevent degradation or salt formation. Specific temperature and humidity recommendations should be confirmed from the Certificate of Analysis (CoA) provided with the shipment.
Stability Considerations: The Cbz protecting group is stable under mildly acidic and basic aqueous conditions but is labile to hydrogenolysis (H2, Pd/C) and strong Lewis or Brønsted acids such as HBr/AcOH or TFA in specific formulations. Avoid prolonged exposure to strong oxidizing agents. The free primary amine may react with carbonyl compounds, anhydrides, and activated electrophiles; store away from such reagents.
Disposal: Dispose of waste material in accordance with local, regional, and national regulations. Do not pour down the drain without verification that disposal is compliant with applicable environmental regulations.
Applications in Medicinal Chemistry and Synthesis
Scaffold for Conformationally Constrained Analogues: The azabicyclo[3.1.0]hexane motif is an important bioisostere and conformational constraint tool in medicinal chemistry. Incorporation of this scaffold into drug candidates can lock bioactive conformations, improve target selectivity, and modulate ADMET properties relative to more flexible acyclic or monocyclic analogues.
Chemoselective Functionalization: The orthogonal protecting group strategy inherent in this molecule — Cbz on the ring nitrogen, free amine at C-1 — enables sequential and chemoselective modification. The primary amine at C-1 can be acylated, sulfonylated, reductively alkylated, or coupled via standard peptide coupling reagents (e.g., HATU, EDC/NHS) to introduce additional pharmacophoric elements. Subsequent Cbz removal under hydrogenolysis conditions liberates the ring nitrogen for further elaboration.
Peptidomimetic Synthesis: As a non-natural amino acid surrogate, the compound can be incorporated into peptide backbones to introduce rigidity and protease resistance. The cyclopropane ring in particular mimics the dihedral angle constraints of certain peptide turn structures.
Fragment-Based Drug Discovery: The compact, three-dimensional, and highly functionalized nature of this bicyclic scaffold makes it an attractive fragment or building block in fragment-based drug discovery (FBDD) campaigns and DNA-encoded library synthesis.
Recommended Protocols for Common Transformations
Acylation of the Primary Amine (C-1): Dissolve the compound in anhydrous dichloromethane (DCM) or dimethylformamide (DMF) under an inert atmosphere (N2 or Ar). Add 1.0–1.5 equivalents of the desired acyl chloride or activated ester in the presence of a non-nucleophilic base (e.g., triethylamine or DIPEA, 2–3 equiv) at 0 °C, then allow to warm to room temperature. Monitor by TLC or LC-MS. Work up with aqueous wash and purify by column chromatography.
Cbz Deprotection by Hydrogenolysis: Dissolve the Cbz-protected substrate in methanol or ethanol (or EtOAc if solubility permits). Add 10% Pd/C (10–20 wt% relative to substrate) under a nitrogen atmosphere, then purge and refill with H2 (1 atm balloon). Stir at room temperature for 2–16 hours monitoring by TLC or LC-MS. Filter through Celite, wash with solvent, and concentrate. Note: the free primary amine at C-1 is not affected by these conditions.
Peptide Coupling: To couple the C-1 primary amine to a carboxylic acid partner, use standard coupling reagents (HATU or T3P) with DIPEA (2–3 equiv) in DMF at room temperature. Ensure the carboxylic acid is not bearing a free amine that could cause racemization or side reactions without appropriate protection.
Quality Check Before Use: Verify compound identity and purity using 1H NMR, HPLC (UV 214/254 nm), and high-resolution mass spectrometry prior to use in sensitive biological or synthetic workflows. Consult the CoA for lot-specific purity data.
Quality, Purity and Regulatory Considerations
Purity Standards: For medicinal chemistry and biological testing applications, a minimum purity of ≥95% (by HPLC) is generally recommended. Consult the Aladdin Certificate of Analysis (CoA) for the specific lot purity, which is available upon request or via the product page. Lot-to-lot consistency should be verified when switching between batches in sensitive assays.
Analytical Characterization: The compound should be characterized by 1H and 13C NMR to confirm regiochemistry and stereochemistry of the bicyclic framework. High-resolution mass spectrometry (HRMS) confirms molecular formula. Chiral HPLC or optical rotation measurements are recommended if enantiopurity is relevant to the application.
Reagent Grade and Research Use: Benzyl 1-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate (B175650) is supplied for research use only and is not intended for diagnostic, therapeutic, or food use. Researchers should verify suitability for their specific application.
Regulatory Compliance: This compound is not classified as a controlled substance under standard international regulations; however, end-users are responsible for compliance with all local import, export, and handling regulations applicable in their jurisdiction.
Frequently asked questions
What is the role of the Cbz group in benzyl 1-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate?
The benzyloxycarbonyl (Cbz) group protects the ring nitrogen at the N-3 position of the bicyclic scaffold, preventing its participation in undesired side reactions during synthetic transformations. This orthogonal protection scheme allows chemists to selectively functionalize the free primary amine at C-1 first, and subsequently remove the Cbz group by hydrogenolysis (H2, Pd/C) to release the ring nitrogen for further elaboration.
How should benzyl 1-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate be stored to maintain stability?
The compound should be stored in a tightly sealed container in a cool, dry, and well-ventilated location, protected from light and moisture. Minimizing exposure to air is advisable given the reactivity of the free primary amine. Always refer to the Certificate of Analysis (CoA) provided by Aladdin for lot-specific storage recommendations.
What makes the azabicyclo[3.1.0]hexane scaffold valuable in drug discovery?
The fused pyrrolidine-cyclopropane framework of the azabicyclo[3.1.0]hexane scaffold imparts conformational rigidity and three-dimensionality to drug candidates, helping to lock bioactive conformations and improve selectivity. The increased sp3 character (Fsp3) is associated with improved solubility and reduced promiscuous binding relative to flat, aromatic-rich molecules, making this scaffold increasingly popular in modern medicinal chemistry.
Can the free primary amine of B175650 be selectively modified without affecting the Cbz group?
Yes. The free primary amine at C-1 can be selectively acylated, sulfonylated, or coupled using standard peptide coupling reagents under mild conditions that do not affect the Cbz carbamate. Reactions should be conducted in anhydrous organic solvents with a suitable non-nucleophilic base, and progress should be monitored by LC-MS or TLC to ensure chemoselectivity.
What analytical methods are recommended to verify the purity and identity of B175650?
Identity confirmation is best achieved by 1H NMR and 13C NMR spectroscopy along with high-resolution mass spectrometry (HRMS). Purity should be assessed by reverse-phase HPLC using UV detection at 214 nm and/or 254 nm. If stereochemical purity is critical, chiral HPLC or measurement of optical rotation is recommended. The Aladdin CoA provides lot-specific analytical data as a primary reference.
References
- Lovering, F.; Bikker, J.; Humblet, C. Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success. J. Med. Chem. 2009, 52, 6752–6756. doi:10.1021/jm901241e
- Mykhailiuk, P. K. Saturated bioisosteres of benzene: where to go next? Org. Biomol. Chem. 2019, 17, 2839–2849. doi:10.1039/C8OB02812E
- Stepan, A. F. et al. Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor. J. Med. Chem. 2012, 55, 3414–3424. doi:10.1021/jm300094u
- Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 4th ed.; Wiley-Interscience: Hoboken, NJ, 2007.
Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
危险品化学品经营许可证(带存储)